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Abstract
Background: Interventional trials have used either the Modification of Diet in Renal Disease (MDRD) or chronic kidney
disease (CKD)-Epidemiology Collaboration (CKD-EPI) equation for determination of estimated glomerular filtration rate
(eGFR) to define whether participants have stages 3–5 CKD.
The equation used to calculate eGFR may influence the number and characteristics of participants designated as having

© 2016 S. Karger AG, Basel
0250–8095/16/0442–0130$39.50/0
E-Mail karger@karger.com
www.karger.com/ajn

CKD. Methods: We examined the classification of CKD at
baseline using both equations in the Systolic Blood Pressure
Intervention Trial (SPRINT). eGFR was calculated at baseline
using fasting serum creatinine values from a central laboratory. Results: Among 9,308 participants with baseline CKD
classification using the 4-variable MDRD equation specified
in the SPRINT protocol, 681 (7.3%) participants were reclassified to a less advanced CKD stage (higher eGFR) and 346
(3.7%) were reclassified to a more advanced CKD stage (lower eGFR) when the CKD-EPI equation was used to calculate
eGFR. For eGFRs <90 ml/min/1.73 m2, participants <75 years
were more likely to be reclassified to a less advanced CKD
stage; this reclassification was more likely to occur in nonblacks rather than blacks. Participants aged ≥75 years were
more likely to be reclassified to a more advanced than a less
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advanced CKD stage, regardless of baseline CKD stage.
Reclassification of baseline CKD status (eGFR <60 ml/
min/1.73 m2) occurred in 3% of participants. Conclusions:
Use of the MDRD equation led to a higher percentage of participants being classified as having CKD stages 3–4. Younger
and non-black participants were more likely to be reclassified as not having CKD using the CKD-EPI equation.
© 2016 S. Karger AG, Basel

Background

The Systolic Blood Pressure Intervention Trial
(SPRINT) trial is a National Institutes of Health (NIH)sponsored trial of blood pressure (BP) control in people
without diabetes mellitus at increased risk of developing
cardiovascular disease (CVD) [1]. Three specific subgroups were targeted for recruitment due to their increased risk of CVD, including those with prior CV events,
age ≥75 years and the presence of stages 3–4 chronic kidney disease (CKD). Accurate classification of CKD will be
important for analytic purposes because many of the primary and secondary outcomes will be analyzed by subgroup, including CKD status. During protocol development, the abbreviated (4-variable) Modification of Diet in
Renal Disease (MDRD) study equation [2] was chosen to
assess for the presence or absence of CKD. Since then, the
CKD-Epidemiology Collaboration (CKD-EPI) equation
[3] has been developed and deemed acceptable, if not preferred method, for estimating glomerular filtration rate
(GFR). Other investigators have reported variability in the
classification of CKD stages based on age and other clinical characteristics of study participants [4–11]. To our
knowledge, no published analysis has determined the potential impact of applying alternatively estimated GFR
(eGFR) equations on defining the presence of CKD in a
randomized clinical trial. We hypothesize that some participants who would be classified as having CKD using the
MDRD equation would not be found to have CKD if eGFR
were calculated using the CKD-EPI equation. In this analysis, we determine the degree of reclassification of CKD
stage and identify participant characteristics associated
with reclassification.

events, ≥75 years and/or the presence of CKD. Details of the intervention and outcomes have been previously published [1, 12].
Exclusion criteria included an eGFR <20 ml/min/1.73 m2 at baseline by the MDRD equation, diabetes mellitus, prior stroke, polycystic kidney disease and moderate- to high-grade proteinuria
(>1,000 mg/day) or albuminuria (>600 mg/day). Participants were
randomized to a systolic BP target of either <140 mm Hg (standard
arm) or <120 mm Hg (intensive arm). The primary composite end
point, including adjudicated CV death, or first myocardial infarction (MI), stroke, heart failure and non-MI acute coronary syndrome was ascertained over a follow-up period of up to 6 years.
The intervention was to be assessed in predefined subgroups, including participants with and without CKD (eGFR 20–<60 ml/
min/1.73 m2 as calculated by the 4-variable MDRD equation) and
participants aged <75 or ≥75 years at baseline. There were several
key secondary outcomes including, in the CKD subgroup, the rate
of end-stage kidney disease (ESKD) or a 50% decline from baseline
eGFR, and in the non-CKD subgroup, a 30% decrease from baseline eGFR with an end value of <60 ml/min/1.73 m2. Participant
selection occurred across the United States with 102 clinical sites
in the United States, including Puerto Rico. Written informed consent was obtained from all participants.
Study Measurements
Standardized questionnaires were completed during screening
in order to characterize participants based on socioeconomic factors. Self-reported race/ethnicity was categorized as white, black or
other and Hispanic or non-Hispanic. The Framingham Risk Score
(FRS) for 10-year CVD risk of ≥15% was calculated using lipid values assessed in the previous 12 months [13]. The occurrence of
cardiovascular and peripheral arterial events during the previous
10 years was obtained at baseline from patient history and a review
of medical records. BP was measured at baseline using a standardized protocol. A central laboratory performed all blood and urine
laboratory determinations. Participants were asked to fast for ≥8 h
on the day that the blood was collected.
The SPRINT Central Lab measured creatinine in serum and
urine on a Roche Chemistry Analyzers (Roche Diagnostics Corporation, Indianapolis, Ind., USA) using a creatinase enzymatic
method with calibration traceable to an isotope dilution mass
spectrometry (IDMS) procedure. Urine albumin was measured by
nephelometry using the Siemens ProSpec nephelometer and a rabbit-derived anti-human albumin antibody. The urine albumin/
creatinine ratio (UACR) was calculated using a spot urine sample
obtained at the baseline visit and measured in milligrams of albumin per gram of creatinine (mg/g). Baseline eGFR in ml/
min/1.73 m2 was calculated by the 4-variable MDRD equation using the serum creatinine concentration obtained at the baseline
visit. CKD categories were defined using Kidney Disease Improving Global Outcomes guidelines, with the proviso that CKD classification was based on a single determination of eGFR [14].

Study Sample
SPRINT is a multicenter, randomized clinical trial of standard
versus more intensive BP control in participants aged ≥50 years
with a heightened risk of CVD, including subgroups of prior CV

Statistical Analysis
For both the MDRD and CKD-EPI study equations, eGFR was
categorized as ≥90, 60–89, 45–59, 30–44 and 15–29 ml/min/1.73 m2.
Baseline characteristics of the SPRINT cohort were then compared
by reclassification status based on the CKD-EPI equation (reclassified to a less advanced CKD stage (higher eGFR), not reclassified
or reclassified to a more advanced CKD stage (lower eGFR) using
(as appropriate) analysis of variance/Kruskal–Wallis tests for con-
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tinuous variables and chi-square tests/Fisher’s exact tests for categorical variables). Based on the 5 × 5 cross-tabulation of eGFR
categories, agreement was also assessed using kappa statistics with
Fleiss–Cohen weights [15]. Of the 9,361 participants randomized,
there were 53 participants in whom CKD status could not be ascertained at baseline, and these participants were excluded from
these analyses. All statistical analyses were performed using SAS
9.4 (SAS Institute, Cary, N.C., USA) or the R Statistical Computing
Environment.

Results

There were 9,308 SPRINT participants in whom CKD
status at baseline was determined. The mean age was
67.9 ± 9.4 years; 65% were men. Racial and ethnic composition included approximately 30% black and 10% Hispanic. Subgroups at baseline included 28.4% with CKD
(eGFRMDRD <60 ml/min/1.73 m2), 28.1% aged ≥75 years
and 20.1% who had prior CVD. Overall, the median
(25th–75th percentile) eGFRMDRD was 71.2 ml/min/
1.73 m2 (58.1–84.4) and the median (25th–75th percentile) UACR was 9.5 mg/g (5.6–21.4).
Compared to the original classification of CKD by the
MDRD equation, 1,027 participants (11.0%) were reclassified into a different CKD category using the CKD-EPI
equation, including 681 participants (7.3%) who were reclassified to a less advanced CKD stage (higher eGFR)
and 346 participants (3.7%) who were reclassified to a
more advanced CKD stage (lower eGFR). Characteristics
associated with a reclassification to a less advanced CKD
stage, based on univariate analysis, included younger age,
female sex, white race, lower FRS, higher low-density lipoprotein cholesterol level, lower high-density lipoprotein cholesterol level, higher diastolic BP, absence of prior
cardiovascular history and lower urine protein or urine
albumin excretion. Selected baseline characteristics of the
SPRINT participants, according to reclassification status,
are shown in table 1.
More than 10% of participants with a baseline MDRD
eGFR of ≥90 ml/min/1.73 m2 were reclassified to a more
advanced CKD stage when eGFR was calculated using the
CKD-EPI equation (fig. 1). Conversely, 8.7, 11.2 and 5.1%
of participants, respectively, with MDRD eGFRs of 60–
89, 45–69 and 30–44 ml/min/1.73 m2 were reclassified to
a less advanced CKD stage when the CKD-EPI equation
was employed. Age has a substantial impact on CKD reclassification in our cohort. For the age category of 50–64
years, 17.9, 25.6 and 11.5% of participants, respectively,
with MDRD GFRs of 60–89, 45–69 and 30–44 ml/
min/1.73 m2 were reclassified to a less advanced stage of
132
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CKD while the level of reclassification to a less advanced
stage of CKD in the age category of ≥75 years was consistently ≤1.5% (fig. 2). Conversely, for the age category of
≥75 years, 66.3, 5.6, 7.6 and 4.8% of participants, respectively, with MDRD GFRs of ≥90, 60–89, 45–69 and 30–44
ml/min/1.73 m2 were reclassified to a more advanced
stage of CKD. Reclassification to a more advanced stage
of CKD in the 50–64 years or older age group rarely occurred across all CKD categories.
Reclassification status based on race and sex is depicted in figure 3. Non-black men and women had similar
patterns of reclassification, with 21–23% reclassification
to a lower eGFR if the MDRD calculated eGFR was ≥90
ml/min/1.73 m2 and higher rates of reclassification to
higher levels of eGFR than to lower levels of eGFR at
MDRD eGFRs ≤90 ml/min/1.73 m2. A similar pattern
was seen for Hispanics; however, there was a higher rate
of reclassification to higher levels of eGFR than in whites.
Black men and women had low levels of reclassification
at eGFRs of ≥90 ml/min/1.73 m2 and were less likely to be
reclassified compared to non-blacks of the same sex at
lower levels of MDRD eGFRs.
There were 2,742 (29.5%) participants who were classified as having CKD using either or both of the estimating equations for eGFR. This subgroup included 198 participants who had an MDRD eGFR <60 ml/min/1.73 m2
and a CKD-EPI eGFR >60 ml/min/1.73 m2 and 85 participants who had an MDRD eGFR >60 ml/min/1.73 m2
and a CKD-EPI eGFR <60 ml/min/1.73 m2 (table 2).
Variables associated with reclassification of this subgroup were similar to that seen in the entire SPRINT
cohort.
The agreement between eGFR categories using the 2
eGFR estimating equations, as determined by weighted
kappa statistics (table 3), was also associated with subject
characteristics, with lower levels of agreement seen in the
50–65 years age group, other races, Hispanic ethnicities
and lower levels of albuminuria.

Discussion

In this large sample of non-diabetic individuals at increased risk of cardiovascular events including more than
one in 4 with CKD, 7.3% of participants were reclassified
to a less advanced CKD stage (higher eGFR) and 3.7%
were reclassified to a more advanced CKD stage (lower
eGFR) when the CKD-EPI equation was used to calculate
eGFR. Age was the most important factor in reclassification. Participants <75 years of age more frequently had a
Rocco et al.

Table 1. Characteristics of SPRINT participants according to reclassification status

No reclassification
Upward to less
(n = 8,281)
advanced CKD
stage (higher eGFR)
using CKD-EPI
(n = 681)
Age, years
50–<65
65–<75
≥75
Sex
Male
Female
Race/ethnicity
White
Black
Hispanic
Other
Education, years
<12
12
>12
Unknown
10-Year, FRS, %
FRS >15%
LDL cholesterol, mg/dl
HDL cholesterol, mg/dl
Systolic BP, mm Hg
Diastolic BP, mm Hg
History of CVD
Previous MI, CABG, PCI, carotid endarterectomy
or carotid stenting
PAD with revascularization
Acute coronary syndrome with or without resting ECG
changes, ECG changes on graded exercise test or
positive cardiac imaging study
50% stenosis of a coronary, carotid or
lower extremity artery
AAA ≥5cm with or without repair
Coronary artery calcium score ≥400 Agatston units
Low ABI (≤0.90)
LVH by computer ECG reading, echogram report or
other cardiac imaging procedure
UACR, mg/g
Albuminuria, mg/g
Unknown
<30
30–<300
≥300
Urine microalbumin, mg/l

Downward to more
advanced CKD stage
(lower eGFR) using
CKD-EPI (n = 346)

p
value

<0.0001
522 (76.7)
147 (21.6)
12 (1.8)

3,269 (39.5)
2,657 (32.1)
2,355 (28.4)

0 (0.0)
77 (22.3)
269 (77.7)

382 (56.1)
299 (43.9)

5,369 (64.8)
2,912 (35.2)

255 (73.7)
91 (26.3)

423 (62.1)
115 (16.9)
130 (19.1)
13 (1.9)

4,740 (57.2)
2,568 (31.0)
822 (9.9)
151 (1.8)

213 (61.6)
100 (28.9)
23 (6.6)
10 (2.9)

<0.0001
<0.0001

0.6324
57 (8.4)
774 (9.3)
39 (11.3)
111 (16.3)
1,343 (16.2)
61 (17.6)
513 (75.3)
6,162 (74.4)
246 (71.1)
0 (0.0)
2 (0.0)
0 (0.0)
13.52 (9.75–19.24) 17.93 (12.1–25.68) 26.28 (17.32–34.91)
298 (43.9)
5,143 (62.3)
286 (82.9)
118.79±36.93
112.23±35.02
103.7±30.56
50.79±13.98
52.89±14.47
56.19±14.64
138.91±16
139.64±15.53
141.61±15.75
81.73±11.16
78.13±11.92
71.03±10.81
125 (18.4)
1,660 (20.0)
82 (23.7)

<0.0001
<0.0001
<0.0001
<0.0001
0.0307
<0.0001
0.1292

87 (12.8)
6 (0.9)

1,119 (13.5)
121 (1.5)

68 (19.7)
1 (0.3)

0.0039
0.0991

30 (4.4)

399 (4.8)

13 (3.8)

0.6698

23 (3.4)
2 (0.3)
4 (0.6)
4 (0.6)

260 (3.1)
57 (0.7)
23 (0.3)
44 (0.5)

13 (3.8)
2 (0.6)
0 (0)
4 (1.2)

0.6974
0.5461
0.2602
0.2587

35 (5.1)
7.94 (5.15–14.66)
38 (5.6)
556 (81.6)
78 (11.5)
9 (1.3)
10 (5–19)

385 (4.6)
9.52 (5.62–21.67)
373 (4.5)
6,363 (76.8)
1,322 (16)
223 (2.7)
11 (6–25)

11 (3.2)
14.29 (7.77–35.06)
11 (3.2)
244 (70.5)
75 (21.7)
16 (4.6)
13 (7–31.75)

0.3698
<0.0001
<0.0001

<0.0001

Values are n (%), mean ± SD, or median (interquartile range).
LDL = Low-density lipoprotein; HDL = high-density lipoprotein; CABG = coronary artery bypass grafting; PCI = percutaneous
coronary intervention; PAD = peripheral artery disease; AAA = abdominal aortic aneurysm; ABI = ankle brachial index; LVH = left
ventricular hypertrophy.
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All participants

MDRD eGFR (ml/min/1.73 m2)

90
(n = 1,570)

Fig. 1. Reclassification rates for SPRINT
participants (n = 9,308) across eGFR categories by the CKD-EPI and MDRD study
equations. Blue bars indicate reclassification to less advanced CKD stage (higher
eGFR); yellow bars, no reclassification; red
bars, downward reclassification to more
advanced CKD stage (lower eGFR).

89.0%

60–89
(n = 5,081)

8.7%

45–59
(n = 1,768)
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89.6%

11.2%

30–44
(n = 732)

1.7%

85.0%

5.1%

3.8%

91.9%

15–29
(n = 157)

3.2%

90
(n = 1,839)

higher eGFR using the CKD-EPI equation, while participants aged ≥75 years more frequently had a lower eGFR
using the CKD-EPI equation. The highest agreement between eGFR equations was seen among black participants, and this group had the lowest frequency of eGFR
reclassification. Reclassification resulting in a change in
(dichotomous) baseline CKD status (<60 ml/min/1.73 m2)
was observed in 3% of participants.
There are several limitations to the use of either the
MDRD equation or the CKD-EPI equation for the estimation of GFR. First, it is important to consider the populations studied for the validation of these 2 estimating
equations. The MDRD equation was validated in 1,085
patients with an eGFR of <60 ml/min/1.73 m2 who did
not have either insulin-requiring diabetes mellitus or a
body weight >160% standard body weight [2].
The MDRD cohort was younger than the SPRINT cohort, with a mean age of 51 ± 13 years and only included
participants with CKD. A subsequent validation study
was conducted in 5,504 individuals who were younger
than those in the SPRINT cohort, with a mean age of 47 ±
13 years [16]. The development and validation of the
134

11.0%

60–89
(n = 4,925)

45–59
(n = 1,625)

30–44
(n = 745)

3.0%

96.8%

15–29
(n = 174)

CKD-EPI eGFR (ml/min/1.73 m2)

CKD-EPI equation included participants who were
younger than those in the SPRINT cohort, with mean
ages of 47 ± 15 and 50 ± 15 years, respectively [2]. In fact,
a minority of the individuals used in either sample were
≥70 years.
Second, other investigators have compared both estimating equations to other more formal measures of GFR
and have found that the CKD-EPI equation has greater
precision and accuracy. Earley et al. [11] performed a systematic review of studies that compared a reference GFR
method with both the MDRD and CKD-EPI eGFR equations. For the 12 studies conducted in North America,
Europe and Australia, the CKD-EPI equation performed
better at higher GFRs (approximately >60 ml/min/
1.73 m2) while the MDRD equation performed better at
lower GFRs. For the 8 studies conducted in Asian or black
populations, which used a modified MDRD equation to
improve performance in the local population, neither
equation performed as well as they did in North American or European populations. The large study (n = 5,238)
of Murata et al. [17] observed that, compared to a gold
standard 125I-iothalamate measured GFR, both estimatRocco et al.

15–29
(n = 60)

45–59
(n = 340)

60–89
(n = 1,891)

90
(n = 1,361)

8.3%

91.7%

CKD-EPI eGFR (ml/min/1.73 m2)

13.0%

30–44
(n = 220)

85.3% 1.7%

8.2%

15–29
(n = 29)

89.5% 2.3%

0.0%

100.0%

15–29
(n = 34)

88.5% 0.0%

95.9% 0.9%

30–44
(n = 207)

11.5%

45–59
(n = 586)

3.2%

45–59
(n = 532)

30–44
(n = 157)

74.4% 0.0%

60–89
(n = 1,636)

11.7%

60–89
(n = 1,693)

25.6%

0.0%

88.3%

90
(n = 415)

45–59
(n = 433)

82.1%

MDRD eGFR (ml/min/1.73 m2)

17.9%

15–29
(n = 55)

60–89
(n = 2,168)

90
(n = 410)

0.0%

30–44
(n = 144)

MDRD eGFR (ml/min/1.73 m2)

90
(n = 973) 100.0%

Color version available online

65 to <75 years

50 to <65 years

CKD-EPI eGFR (ml/min/1.73 m2)

33.7%

60–89
(n = 1,277)

0.0%

45–59
(n = 749)

66.3%

94.4% 5.6%

1.5%

30–44
(n = 355)

90.9% 7.6%

0.3%

45–59
(n = 753)

60–89
(n = 1,341)

90
(n = 63)

15–29
(n = 68)

94.9% 4.8%

0.0%

100.0%

15–29
(n = 85)

90
(n = 187)

30–44
(n = 394)

MDRD eGFR (ml/min/1.73 m2)

75 years or older

CKD-EPI eGFR (ml/min/1.73 m2)

Fig. 2. Reclassification rates for SPRINT participants by age across eGFR categories by the CKD-EPI and MDRD study equations. Blue
bars indicate reclassification to less advanced CKD stage (higher eGFR); yellow bars, no reclassification; red bars, downward reclassification to more advanced CKD stage (lower eGFR).

CKD Classification by MDRD vs.
CKD-EPI

Am J Nephrol 2016;44:130–140
DOI: 10.1159/000448722

135

7.4%

45–59
(n = 390)

91.5% 1.1%
18.2%

30–44
(n = 184)

80.8% 1.0%
11.4%

87.0% 1.6%

15–29
(n = 30)

6.7%

93.3%


(n = 459)
60–89
(n = 2,203)

90.6% 1.4%

45–59
(n = 813)

10.1%

30–44
(n = 316)

86.5% 3.4%
2.5%

15–29
(n = 45)

94.0% 3.5%
4.4%

95.6%

=
(n

=
(n
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89.0% 5.5%

30–44
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Fig. 3. Reclassification rates for SPRINT participants by race (black or white only) Hispanic ethnicity and gender across eGFR categories

by the CKD-EPI and MDRD study equations. Blue bars indicate reclassification to less advanced CKD stage (higher eGFR); yellow bars,
no reclassification; red bars, downward reclassification to more advanced CKD stage (lower eGFR).
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Table 2. Reclassification of SPRINT participants with eGFR <60 ml/min/1.73 m2 based on either MDRD or CKD-EPI study equations

eGFR, ml/min/1.73 m2
eGFRMDRD <60,
eGFRCKD-EPI ≥60
(n = 198)
Age, years
50–<65
65–<75
≥75
Sex
Male
Female
Race/ethnicity
White
Black
Hispanic
Other
Education, years
<12
12
>12
10-Year, FRS, %
FRS >15%
LDL cholesterol, mg/dl
HDL cholesterol, mg/dl
Systolic BP, mm Hg
Diastolic BP, mm Hg
History of CVD
Previous MI, CABG, PCI, carotid endarterectomy
or carotid stenting
PAD with revascularization
Acute coronary syndrome with or without resting
ECG changes, ECG changes on a graded exercise
test or positive cardiac imaging study
50% stenosis of a coronary, carotid or lower extremity artery
AAA ≥5 cm with or without repair
Coronary artery calcium score ≥400 Agatston units
Low ABI (≤0.90)
LVH by computer ECG reading, echogram report
or other cardiac imaging procedure
UACR, mg/g
Albuminuria, mg/g
Unknown
<30
30–<300
≥300
Urine microalbumin, mg/l

eGFRMDRD <60,
eGFRCKD-EPI <60
(n = 2,459)

eGFRMDRD ≥60,
eGFRCKD-EPI <60
(n = 85)

p
value

<0.0001
111 (56.1)
76 (38.4)
11 (5.6)

539 (21.9)
759 (30.9)
1,161 (47.2)

0 (0)
14 (16.5)
71 (83.5)

103 (52.0)
95 (48.0)

1,490 (60.6)
969 (39.4)

62 (72.9)
23 (27.1)

153 (77.3)
16 (8.1)
26 (13.1)
3 (1.5)

1,625 (66.1)
621 (25.3)
175 (7.1)
38 (1.5)

39 (45.9)
43 (50.6)
3 (3.5)
0 (0.0)

0.0033
<0.0001

0.0223
15 (7.6)
22 (11.1)
161 (81.3)
14.21 (9.81–19.89)
91 (46.2)
117.7±32.5
51.28±14.68
136.91±15.47
79.03±11.18
31 (15.7)

280 (11.4)
437 (17.8)
1,742 (70.8)
19.52 (12.64–28.6)
1,617 (65.9)
106.68±34.3
52.76±14.72
139.35±16.12
74.63±12.24
615 (25.0)

11 (12.9)
11 (12.9)
63 (74.1)
27.55 (19.34–33.99)
72 (85.7)
105.46±29.88
55.04±13.9
139.57±14.95
71.44±11.44
15 (17.6)

<0.0001
<0.0001
<0.0001
0.1332
0.1187
<0.0001
0.0046

25 (12.6)
2 (1.0)

445 (18.1)
46 (1.9)

10 (11.8)
1 (1.2)

0.0550
0.8576

8 (4)
8 (4)
1 (0.5)
1 (0.5)
2 (1)

145 (5.9)
94 (3.8)
24 (1.0)
11 (0.4)
16 (0.7)

4 (4.7)
2 (2.4)
0 (0.0)
0 (0.0)
0 (0.0)

0.5707
0.8661
1.0000
0.7298
0.7947

9 (4.5)
8.1 (5.07–18.66)

115 (4.7)
13.92 (6.52–46.01)

9 (4.5)
154 (77.8)
31 (15.7)
4 (2.0)
10 (5–26)

83 (3.4)
1,592 (64.7)
618 (25.1)
166 (6.8)
15 (7–49)

3 (3.5)
14.29 (6.9–30.43)
0 (0.0)
63 (74.1)
17 (20.0)
5 (5.9)
13 (8–37)

0.9705
<0.0001
0.0003

<0.0001

Values are n (%), mean ± SD, or median (interquartile range). LDL = Low-density lipoprotein; HDL = high-density lipoprotein; CABG =
coronary artery bypass grafting; PCI = percutaneous coronary intervention; PAD = peripheral artery disease; AAA = abdominal aortic aneurysm; ABI = ankle brachial index; LVH = left ventricular hypertrophy.

ing equations overestimated GFR in individuals >70 years
of age who had CKD (9% for MDRD eGFR vs. 5% for
CKD-EPI) and underestimated GFR in younger healthy
individuals (–17% for MDRD eGFR vs. –9% for CKDEPI). In a study of 392 elderly individuals who were at

least 74 years of age, Kilbride et al. [5] measured GFR by
the iohexol clearance method and found the that CKDEPI equation appeared less biased and was more accurate
than the MDRD equation. Both equations overestimated
measured GFR; however, this was only significant for the
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Table 3. Agreement between eGFR categories by the CKD-EPI and MDRD study equations

Number

Age, years
50–<65
65–<75
≥75
Sex
Male
Female
Race/ethnicity
White
Black
Hispanic
Other
Race/ethnicity and sex
White female
White male
Black female
Black male
Hispanic female
Hispanic male
FRS >15%
No
Yes
History of CVD
No
Yes
Albuminuria, mg/g
Unknown
<30
30–<300
≥300
a

unweighted

weighteda

3,791
2,881
2,636

0.77 (0.76–0.79)
0.87 (0.85–0.89)
0.84 (0.82–0.85)

0.90 (0.89–0.91)
0.94 (0.93–0.95)
0.93 (0.93–0.94)

6,006
3,302

0.83 (0.82–0.84)
0.82 (0.80–0.84)

0.93 (0.92–0.93)
0.93 (0.93–0.94)

5,376
2,783
975
174

0.81 (0.79–0.82)
0.88 (0.87–0.90)
0.75 (0.71–0.78)
0.78 (0.70–0.87)

0.92 (0.91–0.93)
0.96 (0.95–0.96)
0.90 (0.88–0.92)
0.89 (0.85–0.94)

1,540
3,836
1,258
1,525
449
526

0.80 (0.77–0.82)
0.81 (0.80–0.83)
0.88 (0.86–0.90)
0.89 (0.86–0.91)
0.71 (0.65–0.77)
0.78 (0.73–0.82)

0.92 (0.90–0.93)
0.92 (0.91–0.93)
0.96 (0.95–0.97)
0.95 (0.94–0.96)
0.88 (0.85–0.92)
0.91 (0.89–0.93)

3,553
5,727

0.81 (0.79–0.82)
0.84 (0.83–0.85)

0.93 (0.92–0.93)
0.93 (0.93–0.94)

7,441
1,867

0.83 (0.81–0.84)
0.83 (0.81–0.85)

0.93 (0.92–0.93)
0.94 (0.93–0.94)

422
7,163
1,475
248

0.80 (0.74–0.85)
0.82 (0.80–0.83)
0.86 (0.83–0.88)
0.87 (0.82–0.92)

0.89 (0.86–0.92)
0.91 (0.91–0.92)
0.95 (0.95–0.96)
0.96 (0.95–0.98)

Weighted kappa statistic computed using Fleiss–Cohen weights.

MDRD equation when the measured GFR was ≥60 ml/
min/1.73 m2. This effect was most pronounced for individuals aged ≥80 years.
Third, large retrospective meta-analyses have also
demonstrated that use of the CKD-EPI equation improved risk stratification compared to the MDRD equation. Matsushita et al. [10] examined 1,010,988 participants in the Alberta, Canada, laboratory registry in
whom outcome data were available for all-cause mortality, acute MI, ESKD and a doubling of the serum creatinine concentration. When the CKD-EPI equation
was used instead of the MDRD equation, 22.6% of all
participants (mean age 43.1 ± 11.8 years) were reclassified to a less advanced CKD stage. Conversely, the use
of the CKD-EPI equation reclassified 1.2% of all par138

Kappa statistic (95% CI)
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ticipants (mean age 81.1 ± 6.8 years) to a more advanced CKD stage. The reported prevalence of CKD
stages 3 and 4 changed from 9.2 to 7.3%. Similarly, data
from the Third National Health and Nutrition Examination Survey showed that use of the CKD-EPI equation resulted in 26.9% of the population being reclassified to a less advanced CKD stage and 2.2% being reclassified to a more advanced CKD stage. Characteristics
associated with being reclassified to a less advanced
CKD stage included younger age, female sex and lower
prevalence of CVD and diabetes mellitus [7]. Finally, a
meta-analysis of 45 studies comprising 1,130,472 adults,
including those from the general population, those with
CKD and those at risk for CKD determined that 24.4%
of participants from the general population cohort were
Rocco et al.

reclassified to a less advanced CKD stage when the
MDRD eGFR equation was replaced by the CKD-EPI
equation, while 0.6% were reclassified to a more advanced CKD stage. This reclassification resulted in a decrease in the percentage of participants having stages
3–4 CKD from 8.7 to 6.3%. In the eGFR category of
45–59 ml/min/1.73 m2, as determined by the MDRD
equation, 34.7% of participants were reclassified to less
advanced CKD by the CKD-EPI equation and these reclassified participants had lower levels of events (allcause and cardiovascular mortality or ESKD) compared
to participants who were not reclassified [9]. In all 3
studies, reclassification of CKD with the CKD-EPI
equation improved risk stratification; in the latter study,
this improvement was noted in multiple subgroups including elderly (≥65 years) versus non-elderly, sex, race
and the presence or absence of hypertension and diabetes mellitus.
The strengths of this study include a large, racially
diverse population that includes 30% blacks and 10%
Hispanics as well as measurement of serum creatinine in
a central laboratory using a method that has been standardized using a standardized and validated IDMS
method. The findings from this study are limited by the
lack of a measured GFR as a comparator. Results should
be taken in the context of the study population in
SPRINT; there may be more or less reclassification in
other populations such as in patients with diabetes mellitus.
In conclusion, use of the MDRD equation led to a
higher proportion of SPRINT participants being classified as having CKD stages 3–4. Participants who were
younger or non-black were more likely to be reclassified
as not having CKD when considering the CKD-EPI equation as the criterion standard.
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